Physician profile
Karen Smith
NPI 1215390117
$1,936.78
in general payments reported to CMS, 2019-2025
13 companies · $373 in 2025
The $373 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $274 · 2022: $234 · 2023: $557 · 2024: $497 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,428.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $462.59 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $273.82 | 2021-2024 | Farxiga |
| Ipsen Biopharmaceuticals, INC | $208.19 | 2021-2022 | |
| Novo Nordisk INC | $184.59 | 2023-2025 | Ozempic, Wegovy |
| Amgen INC. | $156.25 | 2021-2023 | Prolia |
| Janssen Biotech, INC. | $129.18 | 2025 | Rybrevant, Carvykti |
| Takeda Pharmaceuticals U.S.A., INC. | $123.89 | 2024 | Fruzaqla |
| Phathom Pharmaceuticals, INC. | $119.29 | 2025 | Voquezna |
| Axsome Therapeutics, INC. | $98.61 | 2023 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $86.14 | 2023 | Pomalyst |
| Genzyme Corporation | $70.84 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.56 | 2023 | Kisqali, Piqray |
| Genentech USA, INC. | $6.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.